Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Internal Medicine"
DOI: 10.1001/jamainternmed.2018.0783
Abstract: Importance Current guidelines recommend prasugrel hydrochloride and ticagrelor hydrochloride as preferred therapies for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). However, it is not well known how frequently these newer… read more here.
Keywords: iqr; inhibitor; p2y12; ticagrelor ... See more keywords
Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2806
Abstract: In closely monitored randomized controlled trials (RCTs), newer P2Y12 agents (ticagrelor and prasugrel) reduced cardiovascular outcomes compared with clopidogrel following percutaneous coronary intervention (PCI) in acute coronary syndrome. However, these RCTs indicated a higher bleeding… read more here.
Keywords: p2y12; major bleeding; prasugrel; clopidogrel ... See more keywords
Contemporary use of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction referred to primary percutaneous coronary interventions in Poland: Data from ORPKI national registry
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-017-1579-9
Abstract: According to guidelines, it is recommended to give P2Y12 inhibitors (preferably ticagrelor or prasugrel) at the time of first medical contact in patients with STEMI. However, in real life antiplatelet treatment strategies are different among… read more here.
Keywords: ticagrelor prasugrel; registry; p2y12 inhibitors; p2y12 ... See more keywords
The role of P2Y12 receptor inhibition in ischemic stroke on microglia, platelets and vascular smooth muscle cells
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-020-02098-4
Abstract: P2Y12 receptors on platelets have long been the main target of antiplatelet drugs. However, a growing number of studies have revealed that P2Y12 receptor activation on microglia and vascular smooth muscle cells (VSMCs) also aggravates… read more here.
Keywords: ischemic stroke; p2y12; vascular smooth; muscle cells ... See more keywords
Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2018 at "American Heart Journal"
DOI: 10.1016/j.ahj.2017.09.012
Abstract: Background The use of the potent oral P2Y12 inhibitors prasugrel and ticagrelor in patients with acute coronary syndromes (ACS) has a favorable net clinical effect compared with clopidogrel and is recommended as first‐line therapy. However,… read more here.
Keywords: p2y12; safety; efficacy; nonelderly patients ... See more keywords
Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2020.08.053
Abstract: BACKGROUND Although oral P2Y12 inhibitors are key in the management of patients with non-ST elevation acute coronary syndrome (NSTE-ACS), the optimal timing of their administration is not well defined. OBJECTIVE to compare downstream and upstream… read more here.
Keywords: administration; p2y12; cardiology; oral p2y12 ... See more keywords
Selection of P2Y12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome.
Sign Up to like & getrecommendations! Published in 2018 at "Progress in cardiovascular diseases"
DOI: 10.1016/j.pcad.2018.01.003
Abstract: The P2Y12 receptor plays a critical role in the amplification of platelet aggregation in response to various agonists and stable thrombus generation at the site of vascular injury leading to deleterious ischemic complications. Therefore, treatment… read more here.
Keywords: risk; p2y12; acute coronary; percutaneous coronary ... See more keywords
Evidence for a PI3-kinase independent pathway in the regulation of Rap1b activation downstream of the P2Y12 receptor in platelets
Sign Up to like & getrecommendations! Published in 2022 at "Platelets"
DOI: 10.1080/09537104.2022.2071855
Abstract: Abstract Platelet activation by adenosine diphosphate (ADP) is mediated through two G-protein-coupled receptors, P2Y1 and P2Y12, which signal through Gq and Gi, respectively. P2Y1 stimulation leads to phospholipase C activation and an increase in cytosolic… read more here.
Keywords: pi3 kinase; p2y12; activation; rap1b activation ... See more keywords
Thrombus remodelling by reversible and irreversible P2Y12 inhibitors.
Sign Up to like & getrecommendations! Published in 2023 at "Platelets"
DOI: 10.1080/09537104.2022.2157805
Abstract: Pharmacological inhibition of the platelet ADP-receptor P2Y12 is a cornerstone in the prevention of atherothrombotic events in adult patients with acute coronary syndrome (ACS). Thienopyridines such as clopidogrel and prasugrel exert their antithrombotic effect by… read more here.
Keywords: p2y12; thrombus remodelling; p2y12 inhibitors; platelet ... See more keywords
Laboratory Monitoring of Platelet P2Y12 Receptor Inhibitors and Reversal of Antiplatelet Agents.
Sign Up to like & getrecommendations! Published in 2019 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqy151
Abstract: OBJECTIVES To review the use of laboratory tests for antiplatelet agents to determine escalation of antiplatelet therapy and for emergent reversal of P2Y12 inhibitors. METHODS A case scenario and review of cardiovascular and neurointerventional literature… read more here.
Keywords: monitoring platelet; p2y12; laboratory monitoring; platelet ... See more keywords
Personalized antithrombotic treatment of cardiovascular disease: a glimpse into the future based on current knowledge.
Sign Up to like & getrecommendations! Published in 2022 at "European heart journal"
DOI: 10.1093/eurheartj/ehac086
Abstract: This Focus Issue on thrombosis and antithrombotic treatment contains the State of the Art Review article ‘Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum’ by Thomas Lüscher from the Royal Brompton… read more here.
Keywords: p2y12; safety; disease; efficacy ... See more keywords